Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma

FRIDAY, Feb. 9, 2024 -- For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news